Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus placebo in active psoriatic arthritis after inadequate response or intolerance to one prior TNF-alpha inhibitor
MOH_2021-11-04_010362Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Efficacy of guselkumab in active psoriatic arthritis and Safety of guselkumab in active psoriatic arthritis. Started Oct 2021; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on MOH_2021-11-04_010362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-04_010362.